0000000001179832

AUTHOR

Giacomo Mancuso

"Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia."

Congenital deficiency of plasma fibrinogen is a hereditary bleeding disorder with an autosomal recessive pattern of inheritance [1] and an estimated incidence of 1–2 per million in the general population [1]. Due to the rarity of the disorder, the available data on the incidence of bleeding episodes, prevalent clinical manifestations and treatment modalities are scarce [2-7]. Afibrinogenemia is sometimes associated with symptoms that are unusual in patients with defects of coagulation factors, such as thrombotic complications and miscarriages [8-12]. However, knowledge on the incidence and significance of these unusual symptoms is influenced by publication bias. Fresh frozen plasma, cryopre…

research product

"A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors"

research product

"Sicilian haemophilia a and b registry comprising phenotypic and genotypic data"

research product

1."IG ANTI D E.V. NEI PAZIENTI PEDIATRICI CON PTA CRONICA REFRATTARI A IVIG E TERAPIA STEROIDEA"

research product

"Prevalence of owerweight and obesity in children form some school of Palermo"

research product

"Prevention of eating disorders(eds) in preadolescent girls form some schools of Palermo: self-esteem, body dissatisfaction and drive for thinness"

research product

A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.

Summary. Aim: A multicenter randomized open-label crossover prospective trial was designed to compare the efficacy, safety, and cost of standard and high dosages of recombinant factor VIIa (rFVIIa) for home treatment of hemarthroses in hemophiliacs with inhibitors. Methods: Patients were instructed to treat, within 6 h from the onset of bleeding, four consecutive hemarthroses of ankles, knees, or elbows, either with the rFVIIa standard dose of 90 μg kg−1 (repeated as necessary every 3 h) or with a single high dose of 270 μg kg−1. Patients who did not achieve a clinical success within 9 h continued rFVIIa treatment with repeated standard doses. Response to treatment was assessed for up to 48…

research product

"A novel nonsense mutation in severe haemophilia B."

research product

"Trattamento con Fattore VIIA Ricombinante (rFVIIA) ad alte dosi in emofilici con inibitore: Studio randomizzato crossover."

research product

"Case Report: embolia polmonare in soggetto in età pediatrica con trombosi venosa profonda."

research product

Relationship between diet in the first year of life, social factors and body weight in preadolescent schoolchildren in Palermo

research product

Confronting the psychological burden of haemophilia

Providing comprehensive care, counselling and support to haemophilic patients, and their parents have always been quite complex for haemophilia treatment centres. Nowadays, starting with recent developments in genetic counselling, prenatal diagnosis and carrier testing, the psychological burden on patients and parents might possibly have increased, compared with even the recent past. The emotional strains and worries associated with a possibly affected newborn and his care through childhood and adolescence may also have a grievous impact on couple dynamics and marital relationship. The impact may be even higher in families in which haemophilia is newly diagnosed. The main psychological prob…

research product

L'AUTOINFUSIONE: ESPERIENZA DEL CENTRO REGIONALE DI RIFERIMENTO "EMOSTASI E TROMBOSI IN ETA' PEDIATRICA" NELL'OSPEDALE DEI BAMBINI DI PALERMO

research product

"Benefits of sport for a haemophilic patient"

research product

THERAPY AND QUALITY OF LIFE IN PATIENTS SUFFERING FROM HAEMOPHILIA B IN WESTERN SICILY

research product

Malformazione adenomatoide cistica del polmone e deficit di fattore VII. Profilassi chirurgica con fattore VII attivato.

The Authors treat the problem of a patient suffering from Cystic Adenomatoid Malformation of the lung, to whom a deficiency of factor VII has been diagnosed, as a consequence of performed coagulatives examinations made before the surgical operation.

research product

Nutritional counselling in overweight and obese children of some schools from Palermo.

research product

"Immunoglobuline anti-D (IG ANTI-D) in pazienti pediatrici con Porpora Trombocitopenica Idiopatica (ITP) Cronica, refrattari alla terapia con immunoglobuline (IVIG) e terapia steroidea."

research product

Gene symbol: f9.

research product

Ultrasound prognostic signs of Hemophilic Arthropathy.

research product

A novel two base pair deletion in the factor V gene associated with severe factor V deficiency

We studied a family in which the proband, a 13-year-old boy, had unmeasurable plasma levels of coagulation factor V antigen and activity. Clinical symptoms were severe, with several episodes of haemorrhages in the mucosal tracts (gastrointestinal, nose and urinary) and recurrent haemarthroses that caused permanent arthropathy. Sequence analysis of the factor V gene demonstrated the presence of a novel 2 base pair (bp) homozygous deletion in exon 13 at positions 2833-2834. This mutation, present in the heterozygous state in the asymptomatic mother and absent in the healthy brother, introduced a frameshift and a premature stop at codon 900. This would predict the synthesis of a truncated fact…

research product

1."IG Anti-D e.v. nei pazienti pediatrici con PTI Cronica refrattari a IVIg e Terapia Steroidea".

research product

"Protective effect of Human-Derived Protein C in Septic Neonatal Mice."

research product

Immune Tolerance Induction (ITI) with FVIII/VWF concentrate in Italian haemophiliacs with previous unsuccessful ITI and/or negative predictors of ITI response.

research product

Una nuova mutazione nell’esone 4 del gene del FVIII causa un quadro di emofilia moderata.

INTRODUZIONE. L’emofilia su scala mondiale rappresenta la più comune diatesi emorragica X linked. In Sicilia circa 140 famiglie sono soggette a tale condizione. Clinicamente l’emofilia è distinta in forma severa, moderata e lieve in base all’attività del fattore VIII (F8). La forma grave dell’emofilia A è caratterizzata dalla assenza di fattore VIII plasmatico e dall’attività del fattore VIII plasmatico < 1% ed è causata per il 50 % dalla inversione dell’introne 22 del gene del fattore VIII e per il 5% dalla inversione dell’introne 1. La restante parte di alterazioni genetiche riguarda numerose mutazioni puntiformi tipo missense, non-sense e frameshift. La forma moderata è dovuta più freque…

research product

"Sicurezza, efficacia e impatto farmacoeconomico della profilassi con refacto in emofilici adulti: studio S.E.PH.I.RE"

research product

Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi® ) in the treatment of von Willebrand disease: a retrospective clinical study

Summary. The goal of therapy in patients with von Willebrand disease (vWD) is to correct the dual defect of primary haemostasis and intrinsic coagulation reflected by low levels of von Willebrand factor (vWF) and factor VIII coagulant activity (FVIII:C). Factor VIII/von Willebrand factor (FVIII/vWF) concentrates are currently the treatment of choice in vWD patients unresponsive to desmopressin (DDAVP). However, only few studies on their clinical use are available so far. The main objective of this study was to retrospectively evaluate the clinical efficacy of a highly purified, doubly virus-inactivated FVIII/vWF concentrate with a high content of FVIII/vWF (Fanhdi®). Twenty-two patients wit…

research product

Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease

Summary Von Willebrand disease (VWD) is an inherited bleeding disorder caused by the quantitative or qualitative deficiency of von Willebrand factor (VWF). Replacement therapy with plasma-derived VWF/factor VIII (FVIII) concentrates is required in patients unresponsive to desmopressin. To assess the efficacy, safety and ease of use of a new, volume-reduced (VR) formulation of VWF/FVIII concentrate Haemate® P in patients requiring treatment for bleeding or prophylaxis for recurrent bleeding or for invasive procedures. Pharmacoeconomic variables were also recorded. Data were analysed using descriptive statistics. This was a multicentre, prospective, observational study. Consecutively enrolled…

research product

HOME CARE AND AUTO INFUSION IN PEDIATRIC HAEMOPHILIAC PATIENTS

research product

"Ultrasonographical images of joints and prognosis value in patients with severe hemophilic arthropathy."

research product

"IMMUNOGLOBULINE ANTI-D (IG ANTI-D) IN PAZIENTI PEDIATRICI CON PORPORA TROMBOCITOPENICA IDIOPATICA (ITP) CRONICA, REFRATTARI ALLA TERAPIA CON IMMUNOGLOBULINE (IGIV) E TERAPIA STEROIDEA.

research product

"Prophylaxis with Factor VIII Protects Children with Hemophilia a from inhibitor Development."

research product

"Immune Tollerance induction (ITI) with plasma derived FVIII in two haemophilic patients with inhibitor previously treated with recombinant FVIII. Disappearance of the inhibitor and improvement of the quality of live."

research product

Trombofilia in età pediatrica: descrizione di un caso di trombosi venosa profonda (TVP) complicata da embolia polmonare (EP.

research product

Preadolescent obesity in schoolchildren from Palermo: analysis of some correlated factors

research product

"Profilassi chirurgica in paziente con deficit di FVII per intervento di osteoma osteoide."

research product

La cartella clinica informatizzata ed il Portale-Internet. (L’esperienza del Centro Di Riferimento Regionale “Emostasi e Trombosi in età pediatrica” dell’Ospedale dei Bambini di Palermo)

research product

"A randomized crossover study of high- and standard-dose recombinant factor VIIa for home treatment of hemarthroses in hemophiliacs with inhibitors."

research product

"Un Caso Interessante di Trombofilia in età evolutiva"

research product

"Complessità nella diagnosi di Malattia di von Willebrand in una paziente pediatrica"

research product

A novel nonsense mutation in exon 2 of the factor IX gene resulting in severe haemophilia B

research product

pROPHYLAXIS VS ON-DEMAND THERAPY THROUGH ECONOMIC REPORT (P.O.T.T.E.R.)study.

research product

"From Care to take care of oneself"

research product

Immune Tolerance Induction (ITI) in patients wuth hemophilia A and inhibitors: the Italian Retrospective-Prospective Registry - the PROFIT Study .

research product

"Novel point mutations in middle form of haemophilia A."

research product

Trombofilia in età pediatrica: descrizione di un caso di TVP complicata da embolia polmonare

research product

"aPCC (FEIBA) home therapy retrospective survey in long-term secondary prophylaxis on hemophilia A patients with Factor VIII inhibitor."

research product

"Dietary calcium intake and evaluation of some influencing factors, in preadolescent schoolchildren form Palermo, for the prevention of dsteoporosis"

research product

Trombofilia in età pediatrica

research product

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study

research product

APCC (FEIBA) home therapy. Long term use: an Italian retrospective survey in Hemophilia patients with FVIII/IX inhibitors

research product